BioCryst shares surge on first annual profit, ORLADEYO sales jump 38%
Q4 earnings crush expectations with 1236% EPS beat, company reaffirms $645M FY2026 guidance
BioCryst Pharmaceuticals reported its first annual profit in company history on Thursday, delivering quarterly earnings that obliterated Wall Street expectations and sending shares of the rare-disease drugmaker sharply higher.
The Durham, North Carolina-based biotechnology company posted fourth-quarter earnings per share of $1.12, far surpassing analyst estimates of $0.08—a remarkable 1,236% surprise, according to the company's SEC filing. Revenue reached $406.6 million for the quarter, crushing projections of $163 million and representing a 149% beat on the top line.
The blockbuster performance was driven by ORLADEYO, the company's oral treatment for hereditary angioedema, which generated full-year 2025 revenue of $601.8 million, up 38% from the prior year. That growth accelerated to 43% year-over-year when excluding European ORLADEYO revenue, following the company's strategic sale of its European assets in 2024.
"Today marks a historic milestone for BioCryst as we deliver our first full year of profitability," the company stated in its earnings announcement. "The strong ORLADEYO performance demonstrates the growing acceptance of our oral therapy among patients and physicians."
The results represent a dramatic turnaround for a company that has struggled for decades to achieve profitability. Founded in 1986, BioCryst spent years developing small-molecule drugs before finding success with ORLADEYO, which won FDA approval in 2020. The drug competes in the hereditary angioedema market against Takeda Pharmaceutical's injectable treatment Takhzyro, though ORLADEYO's oral administration provides a convenient alternative for patients.
BioCryst's management appeared confident in the drug's continued momentum, reaffirming fiscal 2026 guidance for ORLADEYO net revenue between $625 million and $645 million. The midpoint of that range represents roughly 7% year-over-year growth, suggesting a more normalized growth trajectory following this year's explosive performance.
Despite the company's historic profitability milestone and strong guidance, BioCryst shares closed at $7.55 on Thursday, well below their 52-week high of $11.31 and giving the company a market capitalization of approximately $1.89 billion. The stock has faced pressure over the past year amid broader biotechnology sector weakness and concerns about the sustainability of ORLADEYO's growth rate.
Analysts, however, remain overwhelmingly bullish on the stock's prospects. BioCryst currently carries 9 buy or strong-buy ratings from analysts with zero hold or sell recommendations, according to market data. The consensus price target stands at $21.20, implying significant upside from current levels and suggesting analysts believe the market has yet to fully price in the company's profit-generating potential.
The stock's valuation metrics reflect its newfound profitability status. BioCryst now trades at a forward price-to-earnings ratio of 20.37 times, a reasonable multiple for a profitable specialty pharmaceutical company with a flagship therapy in a growing rare disease market. The company's enterprise value-to-revenue ratio of 3.56 times also suggests room for multiple expansion if ORLADEYO continues to deliver on guidance.
Looking ahead, investors will be watching for early 2026 data on patient adherence and market share gains in the hereditary angioedema space. The company's ability to maintain pricing power in an increasingly competitive rare-disease landscape will also be critical to supporting its profitability and delivering on analyst expectations.
The fourth-quarter blowout marks a pivotal moment for BioCryst, transforming it from a perennial money-losing biotech into a profitable pharmaceutical company with a growing commercial franchise. Whether that transformation will be enough to reignite investor enthusiasm and drive the stock toward its analyst price targets remains to be seen, but the company has proven it can deliver—exceedingly well—on its promises to shareholders.